Abstract
The protein kinase family represents both a huge opportunity and a challenge for drug development. The conservation of structural features within the ATP binding cleft initially led to the belief that specificity would be difficult to achieve. This dogma has now been clearly dispelled with the discovery and clinical testing of a group of first generation compounds, which are characterized by a high degree of selectivity towards a variety of oncology targets. The structural basis for selectivity and potency has now been clarified with the crystallization of a number of such targets in complex with inhibitors. The protein kinase inhibitor field is now ripe for the structure based exploitation of additional highly validated targets from a variety of therapeutic areas.
MeSH terms
-
Adenosine Triphosphate / metabolism*
-
Adenylyl Imidodiphosphate / chemistry
-
Anthraquinones / chemistry
-
Binding Sites / drug effects
-
Catalytic Domain / drug effects
-
Cyclin-Dependent Kinases / chemistry
-
Drug Design*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Kinetin
-
Piperazines / chemistry
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Protein-Tyrosine Kinases / drug effects
-
Purines / chemistry
-
Pyridines / chemistry
-
Pyrimidines / chemistry
-
Pyrroles / chemistry
-
Quinazolines / chemistry
-
Receptors, Growth Factor / antagonists & inhibitors
-
Receptors, Growth Factor / drug effects
-
Roscovitine
-
Staurosporine / chemistry
-
Structure-Activity Relationship
Substances
-
Anthraquinones
-
Enzyme Inhibitors
-
Piperazines
-
Purines
-
Pyridines
-
Pyrimidines
-
Pyrroles
-
Quinazolines
-
Receptors, Growth Factor
-
SU 4984
-
SU 5402
-
Roscovitine
-
Adenylyl Imidodiphosphate
-
damnacanthal
-
olomoucine
-
Adenosine Triphosphate
-
Protein-Tyrosine Kinases
-
Cyclin-Dependent Kinases
-
Staurosporine
-
Kinetin